Micheal A Grosso
As Head, Clinical Development for Specialty Medicine at Daiichi-Sankyo, Michael oversees the ongoing global clinical development of edoxaban, a novel factor FXa inhibitor, as well as several novel thrombosis and cardiovascular, renal, ophthalmologic, pain, cell therapy medical products in pipeline development. He has extensive experience in all aspects of clinical development including regulatory affairs with several successful global NDA filings. Prior to joining Daiichi-Sankyo, Michael spent 3 years at Sanofi Aventis as Medical Director, Cardio-Thrombosis where he managed the cardiovascular and thrombosis clinical trials in North America, including with novel FXa inhibitors, low molecular weight heparins, anti-platelet and anti-arrhythmic drugs. Before joining the pharmaceutical industry, Michael served as Senior Research Investigator for the heart failure research group at University of Pennsylvania. As a Board-certified academic cardiothoracic surgeon, he has over 15 years of past clinical experience while also serving as a primary investigator in basic science and clinical research. He has authored or co-authored over 100 abstracts, manuscripts and book chapters and served as a consultant to the pharmaceutical industry for many years prior to joining the industry.